As global biopharmas expand into new markets, they introduce more systems to handle increasing data volumes and business operations, building layers of disconnected data, systems, and processes. While ...

Modella AI has signed a multi-year agreement with AstraZeneca for expediting AI-driven oncology clinical development.

The approval comes amid speculation that AstraZeneca CEO Pascal Soriot is considering delisting its UK stock market listing for the US.

Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marketing authorisation in the European Union (EU).

Brii Biosciences and Joincare Pharmaceutical have signed a licence and technology transfer agreement for BRII-693 for MDR/XDR infections.

The UK’s Labour Government has revealed its ’10-Year Health Plan’ for the country’s National Health Service (NHS). Speaking at a community health centre in London, Health Secretary Wes Streeting ...

BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin leads.

Lynozyfic has the potential to be administered monthly, giving it an advantage over J&J and Pfizer’s marketed products.

Ligand Pharmaceuticals’ subsidiary LNHC has concluded its merger with CHRO Merger Sub to form a new entity, Pelthos Therapeutics.

The U.S. Food and Drug Administration’s (FDA’s) evolving guidance on Computer Software Assurance and AI/ML-Based Software feels like it’s changing faster than you can read it. They’re emphasizing ...

A new podcast from industry experts MarketScan explains why social determinants of health are critical to patient care.

The UK Government is pushing for a single, unified digital patient record within the NHS, but experts have shared cybersecurity concerns.